论文部分内容阅读
随着肿瘤治疗由经验模式发展到循证模式,循证医学已经成为当今的治疗之本。但是循证模式是基于整个患者及患者群体的大量统计学数据,而患者个体产生的治疗效果及治疗损伤差别都很明显,循证医学发展到多学科、多模态、多元信息综合的个体优化治疗的时代。肿瘤患者个体化放化疗是在大量个体的临床、病理和分子基因水平参数上的指导治疗的,是理想的治疗模式~([1])。每一位患者面对放化疗造成的骨髓抑制是影响其预后的一个重要因素,评价放化疗患者的骨
As the development of oncology has evolved from an empirical model to an evidence-based model, evidence-based medicine has become the cornerstone of today’s treatment. However, the evidence-based model is based on a large number of statistical data of the entire patient and patient population, and the difference between the treatment effect and the treatment damage caused by the individual patient is obvious. Evidence-based medicine has been developed to individual optimization of multidisciplinary, multimodal and multivariate information integration The era of treatment. Individualized chemoradiotherapy in cancer patients is the guiding treatment of clinical, pathological and molecular gene level parameters of a large number of individuals and is the ideal treatment mode ~ ([1]). Each patient in the face of radiotherapy and chemotherapy caused by bone marrow suppression is an important factor affecting the prognosis of patients with radiotherapy and chemotherapy to evaluate the bone